A new commercially available radioimmunoassay (RIA) (Abbott-HBem) was used for determination of hepatitis B e-antigen (HBeAg) and its antibody (anti-HBe). Serial serum samples from 20 transiently HBsAg-positive patients with acute hepatitis were tested. In nearly all patients HBeAg could be shown fo
Rapid detection of hepatitis B surface antigen by double antibody radioimmunoassay
✍ Scribed by C. J. Burrell; G. Leadbetter; S. H. Black; W. M. Hunter
- Publisher
- John Wiley and Sons
- Year
- 1978
- Tongue
- English
- Weight
- 416 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
HBsAg and anti‐HBs can be detected by double‐antibody radioimmunoassay in a reliable routine overnight assay of sensitivity approaching that of solidphase immunoradiometric assay. The test requires careful standardisation and regular preparation of I^125^‐HBsAg of appropriate quality, but otherwise uses only small quantities of commercially available reagents. In this paper, the reaction kinetics of the first incubation (test sample + limiting amount of rabbit anti‐HBs), second incubation (reaction mixture + I^125^‐HBsAg) and precipitation reaction (reaction mixture + antirabbit globulin) were examined, to determine the minimum time required for the assay compatible with adequate sensitivity and user convenience; in addition, in order to reduce the time of radioactive counting, the maximum amount of I^125^‐HBsAg per test compatible with a satisfactory assay was examined. It was concluded that, by terminating each reaction before equilibrium was reached, results could be obtained in 2–3 hours with a detection limit similar to the standard overnight procedure. To allow routine examination of large numbers of samples, the possibilities of complete automation of this liquid‐phase type of assay were discussed.
📜 SIMILAR VOLUMES
The increasing use of hepatitis B vaccination has had an overwhelming positive impact on the prevention of hepatitis B viral infection. Mutations in the hepatitis B surface antigen (HBsAg) gene occur as a result of vaccine escape mutants, anti-hepatitis B surface antigen immunotherapy, or in chronic
A chemiluminescent enzyme linked immunosorbent assay (ELISA) for the detection of antibody t o hepatitis B virus surface antigen (anti-HBs) in human serum has been developed. Polystyrene microtitre plates were coated with recombinant, yeast-derived hepatitis B surface antigen (rec-HBsAg). Patient se
Serum hepatitis B core antigen (HBcAg) was investigated in 85 patients with chronic hepatitis B virus (HBV) infection using a modified radioimmunoassay technique, based on high molarity treatment of samples to avoid masking of the antigen by the excess homologous antibody. Eighty-eight percent of HB
## Abstract Antibody to hepatitis B surface antigen (HBsAg) (anti‐HBs) can exist in patients with chronic hepatitis B virus (HBV) infection. To date, little is known about the association of concurrent HBsAg and anti‐HBs (concurrent HBsAg/ anti‐HBs) with hepatocellular carcinoma (HCC). The aim of t
## Abstract Small hepatitis B surface antigen (HBsAg) is considered to be the best marker for the diagnosis of Hepatitis B virus infection. However, HBsAg variants with mutations within the “a” determinant may be poorly or not detected by diagnostic assays. Three anti‐HBsAg monoclonal antibodies (6